CASE STUDY: Driving Better Outcomes Through Targeted Patient Identification

Driving Better Outcomes with Targeted Patient Identification

In implementing the CardioCare platform, a mid-sized health system in the Northeast identified two main goals:

  • Facilitate the identification of patients with moderate valvular heart disease for continued outreach
  • Grow size and reputation of structural heart program to establish them as a referral destination for high-quality care
 

1,279% RETURN ON INVESTMENT WITHIN 7 MONTHS OF USING CARDIOCARE

Related Articles

AI Alliance

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams 

On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.

Real-World Evidence

Acute Valve Syndrome in Aortic Stenosis

“These findings are extremely important and complementary to the recently presented EARLY TAVR Trial, published in the NEJM. The absence of symptoms was traditionally considered a sign of relative safety. However, this study shows how frequent acute valve syndrome is in patients undergoing AVR, and how patients would benefit greatly